Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipilimumab + tyrosinase peptides + gp100 peptides + mart-1 peptides
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides, Vaccines & Immunotherapeutics
- Administration
- Intravenous (ipilimumab), Subcutaneous Or Intradermal (peptide Vaccines; May Vary By Protocol)
01
Overview
This drug is a combination of **ipilimumab**, a fully humanized IgG1 monoclonal antibody targeting CTLA-4 (cytotoxic T-lymphocyte antigen-4), plus a multipeptide vaccine consisting of **gp100**, **MART-1**, and **tyrosinase** peptides. Ipilimumab acts as an **immune checkpoint inhibitor** by blocking CTLA-4, thereby enhancing T-cell activation and antitumor immune responses. The peptide vaccines (gp100, MART-1, tyrosinase) target common melanoma-associated antigens and are designed to promote tumor antigen-specific cytotoxic T-cell responses. The combination has been investigated primarily in metastatic melanoma, aiming to synergistically enhance antitumor immunity.
- Brand names
- Yervoy
- Other names
- ipilimumab plus multipeptide vaccineipilimumab + gp100 + MART-1 + tyrosinase
02
Targets
MART-1/HLA-A*02:01 (Melanoma-associated antigen (Melanoma antigen recognized by T cells 1, Melanocyte protein PMEL, Tyrosinase) peptide-HLA-A*02:01 complex)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PMEL (Melanocyte Protein PMEL)TYR/HLA-A*02:01 (Human leukocyte antigen A*02:01–Tyrosinase peptide complex)
Beyond the preview
Go deeper on ipilimumab + tyrosinase peptides + gp100 peptides + mart-1 peptides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipilimumab + tyrosinase peptides + gp100 peptides + mart-1 peptides.